Hemostemix Inc.

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 19:57:20 21/01/2026 GMT			5-day change	1st Jan Change
0.0900 ^CAD	0.00%		+5.88%	-

01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT
12-30	Hemostemix Inc. announced that it has received CAD 0.48 million in funding	CI

Hemostemix Inc. announced that it has received CAD 0.51844 million in funding

Published on 12/01/2025

S&P Capital IQ

0.00%

+0.33%

-0.09%

+0.53%

+0.17%

On December 2, 2025. Hemostemix Inc. announced that it has closed the transaction.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
HEMOSTEMIX INC.	0.0900CAD	0.00%	+5.88%	12.73M
CANADIAN DOLLAR / JAPANESE YEN	114.8510JPY	+0.33%	+0.68%	-
BRITISH POUND / CANADIAN DOLLAR	1.8555CAD	-0.09%	-0.56%	-
AUSTRALIAN DOLLAR / CANADIAN DOLLAR	0.9398CAD	+0.53%	+1.32%	-
NEW ZEALAND DOLLAR / CANADIAN DOLLAR	0.8093CAD	+0.17%	+1.51%	-

Latest news about Hemostemix Inc.

01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT
12-30	Hemostemix Inc. announced that it has received CAD 0.48 million in funding	CI
12-23	Hemostemix Inc Appoints David B. Alper as Member of Scientific Advisory Board, Effective January 2026	CI
12-09	Hemostemix Inc. announced that it expects to receive CAD 0.96 million in funding	CI
12-01	Hemostemix Inc. announced that it has received CAD 0.51844 million in funding	CI
11-28	Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-17	Hemostemix Inc. announced that it has received CAD 0.280594 million in funding	CI
06/10/25	Hemostemix Inc. announced that it expects to receive CAD 0.7 million in funding	CI
09/09/25	Hemostemix Inc. announced that it expects to receive CAD 0.280594 million in funding	CI
09/09/25	Hemostemix to Seek $0.28 Million in a Private Placement of Shares	MT
29/08/25	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
30/07/25	Hemostemix Inc. announced that it has received CAD 3 million in funding	CI
24/07/25	Hemostemix Raises $2.97 Million in a Private Placement of Share Units	MT
22/07/25	Hemostemix Inc. amended terms of the transaction	CI
09/07/25	Hemostemix Oversubscribed, Closing $2.7 Million Private Placement, Settles $400,000 of Debt	MT
04/07/25	Hemostemix Raises $470,000 in Private Placement	MT
25/06/25	Hemostemix Inc. announced a financing transaction	CI
16/06/25	Hemostemix Inc. announced that it has received CAD 0.469366 million in funding	CI
06/06/25	Hemostemix Inc. - Shareholder/Analyst Call
30/05/25	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/05/25	Hemostemix Raises US$336,500 in a Private Placement of Shares to CytoImmune Therapeutics	MT
11/05/25	Hemostemix Inc. announced that it has received CAD 0.482167 million in funding	CI
29/04/25	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/04/25	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
04/03/25	Hemostemix Inc. announced that it has received $0.51723 million in funding	CI

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Companyâs principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patientâs blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patientâs blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Companyâs proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

Employees

Sector

Biotechnology & Medical Research

Calendar

05-04 - Q4 2025 Earnings Release (Projected)

More about the company